Solriamfetol may curb OSA-associated excessive daytime sleepiness

By Marilynn Larkin, December 11, 2018

Solriamfetol, an investigational norepinephrine-dopamine reuptake inhibitor, improved excessive daytime sleepiness associated with obstructive sleep apnea (OSA) in a phase 3 trial reported last month in Chest.

Click HERE for the full article on MDLinx. This same article also ran in Reuters Health and MD Alert.

Facebook Comments

Enable Dark Mode